More than 30 lawsuits have been filed by parents alleging that taking anti-nausea prescription Zofran for morning sickness during pregnancy caused birth defects in their children including congenital heart defects, cleft lip and cleft palate.
The suits target GlaxoSmithKline LLC’s alleged “off-label” marketing of Zofran, which the U.S. Food and Drug Administration approved in 1991 for the treatment of nausea and vomiting related to chemotherapy and surgery. The cases, citing various clinical studies mostly on animals, allege that GSK failed to warn doctors of the side effects of the drug when used in women to treat morning sickness in the first trimester of pregnancy.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
